These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32780955)

  • 1. Dysostosis Multiplex in Human Mucopolysaccharidosis Type 1 H and in Animal Models of the Disease.
    Hampe CS; Polgreen LE; Lund TC; McIvor RS
    Pediatr Endocrinol Rev; 2020 Aug; 17(4):317-326. PubMed ID: 32780955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling skeletal dysplasia in Hurler syndrome using patient-derived bone marrow osteoprogenitor cells.
    Donsante S; Pievani A; Palmisano B; Finamore M; Fazio G; Corsi A; Biondi A; Tomatsu S; Piazza R; Serafini M; Riminucci M
    JCI Insight; 2024 Mar; 9(5):. PubMed ID: 38456506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
    Wraith JE
    J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).
    Tieu PT; Bach G; Matynia A; Hwang M; Neufeld EF
    Hum Mutat; 1995; 6(1):55-9. PubMed ID: 7550232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of Mexican patients with Mucopolysaccharidosis type I.
    Alonzo-Rojo A; García-Ortiz JE; Ortiz-Aranda M; Gallegos-Arreola MP; Figuera-Villanueva LE
    Genet Mol Res; 2017 Sep; 16(3):. PubMed ID: 28973713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I.
    Brooks DA
    Expert Opin Biol Ther; 2002 Dec; 2(8):967-76. PubMed ID: 12517274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of skeletal x-ray screening for dysostosis multiplex in the early diagnosis of mucopolysaccharidosis.
    Bilgin H; Ayaz E
    Clin Imaging; 2024 Jan; 105():110018. PubMed ID: 37984022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.
    Hampe CS; Eisengart JB; Lund TC; Orchard PJ; Swietlicka M; Wesley J; McIvor RS
    Cells; 2020 Aug; 9(8):. PubMed ID: 32764324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A canine model of human alpha-L-iduronidase deficiency.
    Spellacy E; Shull RM; Constantopoulos G; Neufeld EF
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6091-5. PubMed ID: 6412235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I.
    Faller KME; Ridyard AE; Gutierrez-Quintana R; Rupp A; Kun-Rodrigues C; Orme T; Tylee KL; Church HJ; Guerreiro R; Bras J
    J Vet Intern Med; 2020 Sep; 34(5):1813-1824. PubMed ID: 32785987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities.
    Schuchman EH; Desnick RJ
    J Clin Invest; 1988 Jan; 81(1):98-105. PubMed ID: 3121676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.
    Johnson BA; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2015 Jan; 84():17.17.1-17.17.8. PubMed ID: 25599668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes.
    Scott HS; Litjens T; Nelson PV; Thompson PR; Brooks DA; Hopwood JJ; Morris CP
    Am J Hum Genet; 1993 Nov; 53(5):973-86. PubMed ID: 8213840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients.
    Ashton LJ; Brooks DA; McCourt PA; Muller VJ; Clements PR; Hopwood JJ
    Am J Hum Genet; 1992 Apr; 50(4):787-94. PubMed ID: 1550122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I.
    Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M
    Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.